Denali Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Denali Therapeutics Inc. (DNLI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $10.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-26
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2020-03-31 was $3.70M, a 12.12% increase year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2019-12-31 was $800.00K, a 68.00% decline year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2019-09-30 was $3.90M, a 50.00% increase year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2019-06-30 was $5.10M, a 45.71% increase year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $10.80M, a 1.89% increase from fiscal 2024.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $10.60M, a 12.40% decline from fiscal 2023.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $12.10M, a 3.97% decline from fiscal 2022.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $12.60M, a 73.70% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $10.80M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $10.60M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $12.10M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $12.60M 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $47.90M 10-K · filed 2024-02-28 | |||
| 2020-12-31 | $43.80M 10-K · filed 2023-02-27 | |||
| 2020-03-31 | $3.70M 10-Q · filed 2020-05-07 | $4.50M derived: sum of 2 quarters · filed 2022-02-28 | $8.40M derived: sum of 3 quarters · filed 2022-02-28 | $13.50M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $4.70M derived: sum of 2 quarters · filed 2022-02-28 | $9.80M derived: sum of 3 quarters · filed 2022-02-28 | $13.10M 10-K · filed 2022-02-28 |
| 2019-09-30 | $3.90M 10-Q · filed 2019-11-06 | $9.00M derived: sum of 2 quarters · filed 2019-11-06 | $12.30M 10-Q · filed 2019-11-06 | $14.80M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $5.10M 10-Q · filed 2019-08-06 | $8.40M 10-Q · filed 2019-08-06 | $10.90M derived: sum of 3 quarters · filed 2021-02-26 | $13.50M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $3.30M 10-Q · filed 2020-05-07 | $5.80M derived: sum of 2 quarters · filed 2021-02-26 | $8.40M derived: sum of 3 quarters · filed 2021-02-26 | $11.90M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $5.10M derived: sum of 2 quarters · filed 2021-02-26 | $8.60M derived: sum of 3 quarters · filed 2021-02-26 | $9.80M 10-K · filed 2021-02-26 |
| 2018-09-30 | $2.60M 10-Q · filed 2019-11-06 | $6.10M derived: sum of 2 quarters · filed 2019-11-06 | $7.30M 10-Q · filed 2019-11-06 | $7.40M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $3.50M 10-Q · filed 2019-08-06 | $4.70M 10-Q · filed 2019-08-06 | $4.80M derived: sum of 3 quarters · filed 2020-02-27 | $6.00M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $1.30M 10-Q · filed 2019-05-08 | $1.30M derived: sum of 2 quarters · filed 2020-02-27 | $2.50M derived: sum of 3 quarters · filed 2020-02-27 | $3.00M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $1.20M derived: sum of 2 quarters · filed 2020-02-27 | $1.70M derived: sum of 3 quarters · filed 2020-02-27 | $3.50M 10-K · filed 2020-02-27 |
| 2017-09-30 | $1.20M 10-Q · filed 2018-11-08 | $1.70M derived: sum of 2 quarters · filed 2018-11-08 | $3.50M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $500.00K 10-Q · filed 2018-08-09 | $2.30M 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $1.80M 10-Q · filed 2018-05-11 | |||
| 2016-12-31 | $700.00K 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |